Related Experiment Video
Updated: May 22, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Prospects for gene transfer for clinical heart failure
T Tang1, M H Gao, H Kirk Hammond
1Department of Medicine, University of California San Diego, CA, USA.
Gene Therapy
|April 27, 2012
Summary
Gene transfer shows promise for treating congestive heart failure by improving heart function. Adenylyl cyclase 6 and paracrine-based gene transfer are emerging therapeutic strategies for this condition.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Biotechnology
Background:
- Congestive heart failure (CHF) is a significant health issue with high rates of illness and death.
- Current treatments for CHF have limitations in effectively restoring cardiac function.
Purpose of the Study:
- To review the general principles and applications of cardiac gene transfer.
- To summarize preclinical findings on adenylyl cyclase 6 (AC6) as a therapeutic gene for heart failure.
- To discuss the potential of paracrine-based gene transfer for CHF treatment.
Main Methods:
- Review of preclinical studies and existing literature on cardiac gene transfer.
- Focus on adenylyl cyclase 6 gene therapy strategies.
- Exploration of paracrine signaling mechanisms in heart failure.
Main Results:
- Preclinical data suggest gene transfer is a safe and effective method to enhance the function of failing hearts.
- Adenilyl cyclase 6 has demonstrated therapeutic potential in preclinical models of heart failure.
- Paracrine-based gene transfer presents a novel therapeutic avenue for congestive heart failure.
Conclusions:
- Gene transfer holds significant promise as a future treatment for congestive heart failure.
- Adenilyl cyclase 6 gene therapy is a viable option for improving cardiac function.
- Paracrine-based approaches offer new hope for managing heart failure.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...